Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 231INDUSTRY 123NIH 48NETWORK 6OTHER_GOV 2UNKNOWN 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Sunitinib × Clear all
NCT02626754 2018-06-26

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Taipei Veterans General Hospital, Taiwan

Phase 2 Terminated
13 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT00620347 2013-06-19

Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

National Cancer Center, Korea

Phase 2 Completed
25 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡